Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.8200
+0.0300 (3.80%)
Jul 22, 2025, 4:00 PM EDT
3.80%
Market Cap37.97M
Revenue (ttm)n/a
Net Income (ttm)-3.85M
Shares Out46.31M
EPS (ttm)-0.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,400
Average Volume36,768
Open0.7900
Previous Close0.7900
Day's Range0.7800 - 0.8200
52-Week Range0.5100 - 0.8800
Beta0.81
RSI57.70
Earnings DateAug 22, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.